Cart
sales@molnova.com
Camonagrel
CAS No. 105920-77-2
Camonagrel( —— )
Catalog No. M35990 CAS No. 105920-77-2
Camonagrel is a compound with inhibitory effects on Prostaglandin E2 (PGE2).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 922 | In Stock |
|
| 10MG | 1226 | In Stock |
|
| 25MG | 1853 | In Stock |
|
| 50MG | 2437 | In Stock |
|
| 100MG | 3283 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCamonagrel
-
NoteResearch use only, not for human use.
-
Brief DescriptionCamonagrel is a compound with inhibitory effects on Prostaglandin E2 (PGE2).
-
DescriptionCamonagrel is a compound that has inhibitory effects on Prostaglandin E2. Camonagrel is a potent thromboxane synthase inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorProstaglandin Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number105920-77-2
-
Formula Weight272.3
-
Molecular FormulaC15H16N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(O)(=O)C1C=2C(=CC(OCCN3C=CN=C3)=CC2)CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. M A Villalobos, et al. Effects of camonagrel, a selective inhibitor of platelet thromboxane synthase, on the platelet-subendothelium interaction. Pharmacology. 2003 Sep;69(1):44-50.?
molnova catalog
related products
-
OBE022
OBE022 is a potent, highly selective, orally active antagonist of the contractile PGF2α prostaglandin receptor with Kb of 5.9 nM.
-
Cloprostenol sodium
Cloprostenol sodium is a more water solute crystalline form of cloprostenol than the free acid is a synthetic analog of prostaglandin F2α.
-
Terutroban
Terutroban (S-18886) is a potent, selective antagonist of the thromboxane receptor (Prostanoid TP receptor) that blocks thromboxane induced platelet aggregation and vasoconstriction.
